Doxazosin
- Generic Name
- Doxazosin
- Brand Names
- Cardura
- Drug Type
- Small Molecule
- Chemical Formula
- C23H25N5O5
- CAS Number
- 74191-85-8
- Unique Ingredient Identifier
- NW1291F1W8
- Background
Doxazosin is an alpha-1 antagonist used for the treatment of benign prostatic hypertrophy (BPH) symptoms and hypertension. Other members of this drug class include Prazosin, Terazosin, Tamsulosin, and Alfuzosin. Because of its long-lasting effects, doxazosin can be administered once a day. It is marketed by Pfizer and was initially approved by the FDA in 199...
- Indication
Doxazosin is indicated to treat the symptoms of benign prostatic hypertrophy, which may include urinary frequency, urgency, and nocturia, among other symptoms. In addition, doxazosin is indicated alone or in combination with various antihypertensive agents for the management of hypertension. Off-label uses of doxazosin include the treatment of pediatric hype...
- Associated Conditions
- Benign Prostatic Hyperplasia (BPH), Hypertension, Ureteric calculus
- Associated Therapies
- -
Alfuzosin for Medical Expulsion Therapy of Ureteral Stones
- Conditions
- Interventions
- First Posted Date
- 2008-07-11
- Last Posted Date
- 2012-04-27
- Lead Sponsor
- United States Naval Medical Center, San Diego
- Target Recruit Count
- 240
- Registration Number
- NCT00713739
- Locations
- 🇺🇸
Naval Medical Center San Diego, San Diego, California, United States
Black Education and Treatment of Hypertension (BEAT HTN)
- First Posted Date
- 2008-04-21
- Last Posted Date
- 2012-12-04
- Lead Sponsor
- Creighton University
- Target Recruit Count
- 99
- Registration Number
- NCT00661895
- Locations
- 🇺🇸
Creighton Community Health Center, Omaha, Nebraska, United States
Nephropathy In Type 2 Diabetes and Cardio-renal Events
- First Posted Date
- 2007-09-27
- Last Posted Date
- 2020-08-03
- Lead Sponsor
- University of Campania "Luigi Vanvitelli"
- Target Recruit Count
- 850
- Registration Number
- NCT00535925
- Locations
- 🇮🇹
Department of Advanced Medical and Surgical Sciences, Università della Campania "Luigi Vanvitelli", Naples, Italy, Naples, Italy
Effects of Intensive Long-Term Vasodilation in Hypertensive Patients With Microvascular Angina Pectoris
- Conditions
- Interventions
- First Posted Date
- 2007-01-22
- Last Posted Date
- 2009-05-06
- Lead Sponsor
- University of Aarhus
- Target Recruit Count
- 10
- Registration Number
- NCT00424801
- Locations
- 🇩🇰
Aarhus Hospital, Aarhus, Denmark
Effects of Combination Therapy With Alpha-1 Blocker (Bunazosin or Doxazosin) in the Treatment of Patients With Mild to Moderate Essential Hypertension
- Conditions
- Interventions
- First Posted Date
- 2005-08-15
- Last Posted Date
- 2013-05-14
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 93
- Registration Number
- NCT00130156
- Locations
- 🇨🇳
National Taiwan University Hospital., Taipei, Taiwan
Medical Therapy of Prostatic Symptoms
- Conditions
- Interventions
- First Posted Date
- 2001-08-06
- Last Posted Date
- 2018-09-28
- Target Recruit Count
- 3407
- Registration Number
- NCT00021814
- Locations
- 🇺🇸
University of California, La Jolla, California, United States
🇺🇸University of Maryland, Baltimore, Maryland, United States
🇺🇸New York University School of Medicine, New York, New York, United States
Genetics of Hypertension Associated Treatments (GenHAT)
- First Posted Date
- 2000-09-26
- Last Posted Date
- 2024-04-26
- Lead Sponsor
- Donna Arnett, 257-5678
- Target Recruit Count
- 37939
- Registration Number
- NCT00006294
- Locations
- 🇺🇸
University of Kentucky, Lexington, Kentucky, United States
Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
Treatment of Mild Hypertension Study (TOMHS)
- Conditions
- First Posted Date
- 1999-10-28
- Last Posted Date
- 2016-02-25
- Lead Sponsor
- University of Minnesota
- Registration Number
- NCT00000522
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.